Elicera Therapeutics announces that the Drug Safety Board (DSMB) has reviewed data from cohort 2 of the phase I/IIa CARMA trial with CAR T-cell therapy ELC-301 for B-cell lymphoma and recommends continuation as planned. The study, in collaboration with Uppsala University, includes dose escalation (phase I, 12 patients) and dose expansion (phase IIa, 6 patients). Previous data from cohort 1 showed promising results with complete response in two patients without serious side effects. The third cohort is now starting.
|
Published August 25, 2025
Elicera continues CARMA study after DSMB approval
Notes
Flerie and Lipum enter into merger plan
Johnson & Johnson acquires Halda Therapeutics for $3 billion
Magle Group submits application for EmboCept S
Quia Pharma is delisted from Nasdaq
Stenocare acquires CannGros
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
NEWSLETTER
Today's news roundup
News roundup Tuesday, November 18
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account